This move is archived. Current quotes and coverage live on the stock page.
Get HBP alerts:
Helix BioPharma Corp. faced a tough trading day, with shares down 3.45% as investors reacted to the latest developments.
Helix BioPharma Corp. (HBP.TO) saw its stock price drop during the last trading session, closing at CA$1.40. This 3.45% decline raises concerns about investor confidence and the company's future in the competitive biotech sector.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$145.12M
52W high
$5.40
52W low
$1.10
1W change
-5.00%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 31.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+31.6% Upside
Current Price
C$1.90
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
39.4%
Annualized
90-Day Vol
58.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.27
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.02 | C$1.76 โ C$2.31 |
| 60 trading days | C$2.14 | C$1.77 โ C$2.59 |
| 90 trading days | C$2.27 | C$1.79 โ C$2.88 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should stay cautious with Helix BioPharma as it navigates a challenging market, especially given the lack of recent positive news and ongoing financial issues.
Stock Down 3.45% in Last Session
Helix BioPharma's market cap is CA$110.75 million, highlighting its small-cap status and the volatility that comes with it.
Bull case
If Helix BioPharma can successfully advance its oncology programs and secure additional funding, it could turn things around and regain investor interest.
Bear case
On the other hand, continued losses and a lack of significant developments could further shake investor confidence, leading to a longer downturn in stock performance.
Market Reaction to Helix BioPharma's Performance
Advertisement
The recent drop in Helix BioPharma's stock price stems from several factors, including the absence of positive news and ongoing concerns about its financial health. With a market cap of CA$110.75 million, the company is in a delicate position, especially in the competitive biotech landscape.
Investors Should Stay Informed
Given the volatility of small-cap biotech stocks like Helix BioPharma, investors are advised to keep a close eye on the company's developments. Any progress in its oncology programs or improvements in financial stability could impact future stock performance. For more insights, check out our detailed analysis on Helix BioPharma Corp..
Looking Ahead
As Helix BioPharma continues to work on its strategic initiatives, the focus will be on its ability to secure funding and advance its therapeutic programs. Investors should carefully weigh the risks and potential rewards, as the company's future depends on successfully executing its plans. For ongoing updates, visit our stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
